Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Liabilities (2016 - 2026)

Gyre Therapeutics has reported Total Liabilities over the past 16 years, most recently at $23.8 million for Q4 2025.

  • Quarterly Total Liabilities fell 11.68% to $23.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.8 million through Dec 2025, down 11.68% year-over-year, with the annual reading at $23.8 million for FY2025, 11.68% down from the prior year.
  • Total Liabilities was $23.8 million for Q4 2025 at Gyre Therapeutics, up from $22.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $38.1 million in Q4 2023 and troughed at $1.6 million in Q3 2022.
  • The 5-year median for Total Liabilities is $17.2 million (2021), against an average of $18.4 million.
  • Year-over-year, Total Liabilities crashed 90.76% in 2022 and then skyrocketed 315.17% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $14.6 million in 2021, then decreased by 13.98% to $12.5 million in 2022, then surged by 203.65% to $38.1 million in 2023, then fell by 29.06% to $27.0 million in 2024, then fell by 11.68% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Total Liabilities are $23.8 million (Q4 2025), $22.0 million (Q3 2025), and $23.2 million (Q2 2025).